Mylan Requests Review of Two Patents for Sanofi’s Lantus Insulin

Mylan challenged two patents on Sanofi’s insulin glargine formulation, Lantus, and is requesting an inter partes review by the PTO’s Patent and Trial Appeal Board.
Source: Drug Industry Daily